Article Sidebar
Published:
May 25, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Influence of Ang-(1-7) intervention on ACE2-Ang (1-7)-Mas pathway activity, hepatic glucose metabolism and insulin resistance in type-2 diabetic rats
Abstract
Purpose: To study the effects of angiotensin-(1-7) (angiot (1-7) intervention on angiotensin converting enzyme (ACE)-angiot-(1-7)-Mas pathway, hepatic glucose metabolism, and insulin resistance in rats with type 2 diabetes.
Methods: Thirty-six Sprague Dawley rats were randomly divided into normal control, diabetic control and study groups (12 rats per group). Rats in the normal group were fed normal feed, while rats in the observation and diabetic control groups were type-2 diabetes model, and were given subcutaneous injection of angiot-(1-7) for 8 weeks. Serum insulin resistance index (IRI) and fasting insulin (FINS) were assayed. Other parameters measured were the levels of ACE2 and Mas receptor mRNA in liver tissues.
Results: The levels of FINS in the study and control groups decreased, relative to normal control, while the levels of IRI was elevated (p < 0.05). There were significant increases in study group levels of Mas and ACE2, while angiot-(1-7) was lower, relative to control group (p < 0.05). The expressions of ACE2 and Mas receptors in study and diabetic control rats groups were downregulated, when compared to normal control. The expressions of ACE2 and Mas receptors also decreased in the study group exposed to angiot-(1-7) (p < 0.05).
Conclusion: Angiot-(1-7) significantly increases the levels of FINS and IR, improves hepatic glucose metabolism and enhances ACE2-angiot-(1-7)-Mas pathway. Thus, angiot-(1-7) may be a new drug candidate for the treatment of type 2 diabetes.
